Emmis Acquisition (EMIS) vs Korro Bio (KRRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Korro Bio (KRRO) has outperformed Emmis Acquisition (EMIS) over the past year, gaining 93.9% versus a gain of 4.4%. Korro Bio is the larger company by market cap ($167.2 million vs $163.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EMIS | KRRO |
|---|---|---|
| Share price | $10.36 | $12.18 |
| Market cap | $163.36M | $167.18M |
| 1-day change | +0.15% | -0.08% |
| YTD return | +4.07% | +52.06% |
| 1-year return | +4.39% | +93.95% |
| 5-year return | — | -95.67% |
| EPS (TTM) | — | $-8.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $6.39M |
| Revenue growth (YoY) | — | +181.46% |
| Net income (latest FY) | — | $-117.26M |
| Operating margin | — | -1906.37% |
| Net margin | — | -1834.48% |
| 52-week high | $10.38 | $17.35 |
| 52-week low | $9.92 | $5.20 |
| Distance from 52-week high | -0.24% | -29.81% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +76.52% |
| Average volume | 16.19K | 186.03K |
| Shares outstanding | 11.94M | 13.73M |
| Employees | — | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRRO has outperformed EMIS by 89.6 percentage points over the past year.
About Emmis Acquisition
EMIS stock →Emmis Acquisition Corp. focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
Health Care · Biotechnology: Pharmaceutical Preparations
About Korro Bio
KRRO stock →Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
EMIS vs KRRO FAQ
Which is bigger, Emmis Acquisition or Korro Bio?
Korro Bio (KRRO) is larger, with a market capitalization of $167.18M compared with $163.36M for Emmis Acquisition (EMIS).
Which stock has performed better over the past year, EMIS or KRRO?
KRRO returned +93.95% over the past 12 months, compared with +4.39% for EMIS (price return, excluding dividends). Past performance does not predict future results.
Are Emmis Acquisition and Korro Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.